Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

Related Keywords

Astellas Pharma ,Immatics Incyte ,Crown Bioscience ,Jason Luke ,Immunocore Incyte ,Pembrolizumab Keytruda ,Trex Bio ,Codiak Biosciences ,Bristol Myers Squibb ,Serono ,Novartis ,Pfizer ,Hillman Cancer Center ,Cancer Immunotherapeutic Center ,Gilead Sciences ,Immunotherapy Program ,Cstone Pharmaceuticals ,Tizona Therapeutics Inc ,Division Of Hematology Oncology ,Checkmate Pharmaceuticals ,Corvus Pharmaceuticals ,Genentech ,Bright Peak Therapeutics ,Day One Therapeutics ,Endeavor Biomedicines ,Flame Biosciences ,Hotspot Therapeutics ,Inzen Therapeutics ,Partner Therapeutics ,Reflexion Medical ,Ribon Therapeutics ,Rubius Therapeutics ,Silicon Therapeutics ,Tempest Therapeutics ,Werewolf Therapeutics ,Xilio Therapeutics ,Array Biopharma ,Ikena Oncology ,Moderna Therapeutics ,Scholar Rock ,Tizona Therapeutics ,Trishula Therapeutics ,Actym Therapeutics ,Arch Oncology ,Kanaph Therapeutics ,Mavu Pharmaceutical ,Melanoma ,Advanced Melanoma ,Skin Cancer ,Pd L1 Inhibitor ,Immunotherapy ,Immune Checkpoint Inhibitor ,Pici ,Pasco ,Asco Annual Meeting ,Pembrolizumab ,Adjuvant ,